J. Goldman & Co’s VYNE Therapeutics VYNE Stock Holding History

J. Goldman & Co’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-567	Closed	-$64K	–	541
2020 Q4	$64K	Hold	567	–	–	﹤0.01%	350
2020 Q3	$68K	Hold	567	–	–	﹤0.01%	295
2020 Q2	$71K	Buy	567 +289	+104%	+$39.1K	﹤0.01%	256
2020 Q1	$54K	Buy	+278	New	+$87.2K	0.01%	229

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

J. Goldman & Co's VYNE Position: Q1 2021 in Review

J. Goldman & Co sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 567 shares — an estimated $64K sold.

J. Goldman & Co first reported a position in VYNE in Q1 2020 and held it in 4 quarters. The position peaked at $71K in Q2 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

J. Goldman & Co reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
J. Goldman & Co sold 567 VYNE Therapeutics shares in Q1 2021, an estimated $64K.
J. Goldman & Co first reported a position in VYNE Therapeutics in Q1 2020 and held it in 4 quarters.
J. Goldman & Co's VYNE Therapeutics position peaked at $71K in Q2 2020.
89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.